Top

Published in:

01-01-2018 | Review Article

Cognitive and behavioral disorders in Parkinson’s disease: an update. II: behavioral disorders

Authors: Luigi Trojano, Costanza Papagno

Published in: Neurological Sciences | Issue 1/2018

Abstract

Patients with Parkinson’s disease (PD) can experience several behavioral symptoms, such as apathy, agitation, hypersexuality, stereotypic movements, pathological gambling, abuse of antiparkinsonian drugs, and REM sleep behavioral disorders. Psychoses and hallucinations, depression and anxiety disorders, and difficulties in recognizing and experiencing emotions also impair behavior and can cause severe psychosocial problems in patients with PD. Symptoms can be present since early stages of the disease, sometimes even before the appearance of classical motor symptoms, likely in relation to dopamine depletion in basal ganglia and/or to dysfunctions of other neurotrasmitter systems, and others can develop later, in some cases in relation to dopaminergic treatment. In this paper, we review recent literature, with particular attention to the last 5 years, on the main behavioral and emotional disturbances described in PD patients as well as the hypothesized neurofunctional substrate of such impairments. Finally, we provide some suggestions on the most suitable instruments to check and assess PD-associated behavioral defects over time.

Balestrino R, Martinez-Martin P (2017) Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J Neurol Sci 373:173–178. https://doi.org/10.1016/j.jns.2016.12.060 CrossRefPubMed

Papagno C, Trojano L (2017) Cognitive and behavioural disorders in Parkinson’s disease: an update. I: cognitive impairments. Neurol Sci. Submitted

Haber SN (2014) The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 282C:248–257CrossRef

Criaud M, Christopher L, Boulinguez P, Ballanger B, Lang AE, Cho SS, Houle S, Strafella AP (2016) Contribution of insula in Parkinson’s disease: a quantitative meta-analysis study. Hum Brain Mapp 37:1375–1392. https://doi.org/10.1002/hbm.23109 CrossRefPubMedPubMedCentral

Uddin LQ (2015) Salience processing and insular cortical function and dysfunction. Nat Rev Neurosci 16:55–61. https://doi.org/10.1038/nrn3857 CrossRefPubMed

Adolfi F, Couto B, Richter F, Decety J, Lopez J, Sigman M, Manes F, Ibáñez A (2017) Convergence of interoception, emotion, and social cognition: a twofold fMRI meta-analysis and lesion approach. Cortex 88:124–142. https://doi.org/10.1016/j.cortex.2016.12.019 CrossRefPubMed

Radakovic R, Davenport R, Starr JM, Abrahams S (2017) Apathy dimensions in Parkinson’s disease. Int J Geriatr Psychiatry. https://doi.org/10.1002/gps.4697

Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P (2015) Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14:518–531. https://doi.org/10.1016/S1474-4422(15)00019-8 CrossRefPubMed

den Brok MG, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RM, Richard E (2015) Apathy in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 30:759–769. https://doi.org/10.1002/mds.26208 CrossRef

10.

Varanese S, Perfetti B, Ghilardi MF, Di Rocco A (2011) Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One 6:e17846CrossRefPubMedPubMedCentral

11.

Santangelo G, Vitale C, Trojano L et al (2015) Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson’s disease: a prospective longitudinal study. Eur J Neurol 22:253–260. https://doi.org/10.1111/ene.12467 CrossRefPubMed

12.

Wen MC, Chan LL, Tan LC, Tan EK (2016) Depression, anxiety, and apathy in Parkinson’s disease: insights from neuroimaging studies. Eur J Neurol 23:1001–1019. https://doi.org/10.1111/ene.13002 CrossRefPubMed

13.

Baggio HC, Segura B, Garrido-Millan JL, Marti MJ, Compta Y, Valldeoriola F, Tolosa E, Junque C (2015) Resting-state frontostriatal functional connectivity in Parkinson’s disease-related apathy. Mov Disord 30:671–679. https://doi.org/10.1002/mds.26137 CrossRefPubMed

14.

Skidmore FM, Yang M, Baxter L et al (2013) Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. NeuroImage 81:484–495. https://doi.org/10.1016/j.neuroimage.2011.07.012 CrossRefPubMed

15.

Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 30:121–127. https://doi.org/10.1002/mds.26016 CrossRefPubMed

16.

de la Riva P, Smith K, Xie SX, Weintraub D (2014) Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83:1096–1103. https://doi.org/10.1212/WNL.0000000000000801 CrossRefPubMedPubMedCentral

17.

Jiménez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz MC (2015) Dyskinesias and impulse control disorders in Parkinson’s disease: from pathogenesis to potential therapeutic approaches. Neurosci Biobehav Rev 56:294–314. https://doi.org/10.1016/j.neubiorev.2015.07.010 CrossRefPubMed

18.

Santangelo G, Raimo S, Barone P (2017) The relationship between impulse control disorders and cognitive dysfunctions in Parkinson’s disease: a meta-analysis. Neurosci Biobehav Rev 77:129–147. https://doi.org/10.1016/j.neubiorev.2017.02.018 CrossRefPubMed

19.

Napier TC, Corvol JC, Grace AA, Roitman JD, Rowe J, Voon V, Strafella AP (2015) Linking neuroscience with modern concepts of impulse control disorders in Parkinson’s disease. Mov Disord 30:14114–14119. https://doi.org/10.1002/mds.26068 CrossRef

20.

Carriere N, Lopes R, Defebvre L, Delmaire C, Dujardin K (2015) Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease. Neurology 84:2116–2123. https://doi.org/10.1212/WNL.0000000000001619 CrossRefPubMed

21.

Tessitore A, Santangelo G, De Micco R et al (2016) Cortical thickness changes in patients with Parkinson’s disease and impulse control disorders. Parkinsonism Relat Disord 24:119–125. https://doi.org/10.1016/j.parkreldis.2015.10.013 CrossRefPubMed

22.

Goodarzi Z, Mrklas KJ, Roberts DJ, Jette N, Pringsheim T, Holroyd-Leduc J (2016) Detecting depression in Parkinson disease: a systematic review and meta-analysis. Neurology 87:426–437. https://doi.org/10.1212/WNL.0000000000002898 CrossRefPubMedPubMedCentral

23.

Santangelo G, Vitale C, Trojano L et al (2014) Subthreshold depression and subjective cognitive complaints in Parkinson’s disease. Eur J Neurol 21:541–544. https://doi.org/10.1111/ene.12219 CrossRefPubMed

24.

Ehrt U, Brønnick K, Leentjens AF, Larsen JP, Aarsland D (2006) Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatry 21:252–258CrossRefPubMed

25.

Rod NH, Bordelon Y, Thompson A, Marcotte E, Ritz B (2013) Major life events and development of major depression in Parkinson’s disease patients. Eur J Neurol 20:663–670. https://doi.org/10.1111/ene.12019 CrossRefPubMed

26.

Chagas MHN, Tumas V, Pena-Pereira MA, Machado-de-Sousa JP, Carlos Dos Santos A, Sanches RF, Hallak JEC, Crippa JAS (2017) Neuroimaging of major depression in Parkinson’s disease: cortical thickness, cortical and subcortical volume, and spectroscopy findings. J Psychiatr Res 90:40–45. https://doi.org/10.1016/j.jpsychires.2017.02.010 CrossRefPubMed

27.

Hu X, Song X, Li E, Liu J, Yuan Y, Liu W, Liu Y (2015) Altered resting-state brain activity and connectivity in depressed Parkinson’s disease. PLoS One 10:e0131133. https://doi.org/10.1371/journal.pone.0131133 CrossRefPubMedPubMedCentral

28.

Borgonovo J, Allende-Castro C, Laliena A, Guerrero N, Silva H, Concha ML (2017) Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson’s disease. Parkinsonism Relat Disord 35:17–24. https://doi.org/10.1016/j.parkreldis.2016.11.009 CrossRefPubMed

29.

Zhu K, van Hilten JJ, Marinus J (2017) Onset and evolution of anxiety in Parkinson’s disease. Eur J Neurol 24:404–411. https://doi.org/10.1111/ene.13217 CrossRefPubMed

30.

Wee N, Kandiah N, Acharyya S, Chander RJ, Ng A, WL A, Tan LC (2016) Depression and anxiety are co-morbid but dissociable in mild Parkinson’s disease: a prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord 23:50–56. https://doi.org/10.1016/j.parkreldis.2015.12.001 CrossRefPubMed

31.

Broen MP, Narayen NE, Kuijf ML, Dissanayaka NN, Leentjens AF (2016) Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 31:1125–1133. https://doi.org/10.1002/mds.26643 CrossRefPubMed

32.

Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P (2016) Emotional manifestations of PD: neurobiological basis. Mov Disord 31:1103–1113. https://doi.org/10.1002/mds.26587 CrossRefPubMed

33.

Rutten S, Vriend C, van der Werf YD, Berendse HW, Weintraub D, van den Heuvel OA (2017) The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson’s disease. Parkinsonism Relat Disord 39:31–36. https://doi.org/10.1016/j.parkreldis.2017.01.015 CrossRefPubMed

34.

Dissanayaka NN, Lawson RA, Yarnall AJ et al (2017) Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson’s disease. Parkinsonism Relat Disord 36:63–68. https://doi.org/10.1016/j.parkreldis.2017.01.001 CrossRefPubMedPubMedCentral

35.

Pirogovsky-Turk E, Moore RC, Filoteo JV, Litvan I, Song DD, Lessig SL, Schiehser DM (2017) Neuropsychiatric predictors of cognitive decline in Parkinson’s disease: a longitudinal study. Am J Geriatr Psychiatry 25(3):279–289. https://doi.org/10.1016/j.jagp.2016.10.004 CrossRefPubMed

36.

Picillo M, Santangelo G, Erro R, Cozzolino A, Amboni M, Vitale C, Barone P, Pellecchia MT (2017) Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. Parkinsonism Relat Disord 37:106–110. https://doi.org/10.1016/j.parkreldis.2017.02.010 CrossRefPubMed

37.

Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C (2011) Potential mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev 35:556–564. https://doi.org/10.1016/j.neubiorev.2010.06.007 CrossRefPubMed

38.

Barrett M, Smolkin ME, Flanigan JL, Shah BB, Harrison MB, Sperling SA (2017) Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2017.07.011

39.

Lenka A, Herath P, Christopher R, Pal PK (2017) Psychosis in Parkinson’s disease: from the soft signs to the hard science. J Neurol Sci 379:169–176CrossRefPubMed

40.

Ravina B, Marder K, Fernandez HH et al (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068CrossRefPubMed

41.

Factor SA, McDonald WM, Goldstein FC (2017) The role of neurotransmitters in the development of Parkinson’s disease-related psychosis. Eur J Neurol. https://doi.org/10.1111/ene.13376

42.

Martinez-Martin P, Leentjens AFG, de Pedro-Cuesta J, Chaudhuri KR, Schrag AE, Weintraub D (2016) Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson’s disease. Mov Disord 31:270–279. https://doi.org/10.1002/mds.26522 CrossRefPubMed

43.

Perry EK, Perry RH (1995) Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 28:240–258CrossRefPubMed

44.

Janzen J, van‘t Ent D, Lemstra AW, Berendse HW, Barkhof F, Foncke EM (2012) The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol 259:147–154CrossRefPubMed

45.

Collerton D, Perry E, McKeith I (2005) Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 28:737–757 discussion 757-794PubMed

46.

Ehgoetz Martens KA, Lewis SJG (2017) Pathology of behavior in PD: what is known and what is not? J Neurol Sci 374:9–16CrossRefPubMed

47.

Goetz CG, Vaughan CL, Goldman JG, Stebbins GT (2013) I finally see what you see: Parkinson’s disease visual hallucinations captured with functional neuroimaging. Mov Disord 29:115–117CrossRefPubMed

48.

Yao C, Pang S, Chang RS, Lau H et al (2016) Multimodal MRI of the hippocampus in Parkinson’s disease with visual hallucinations. Brain Struct Funct 221:287–300CrossRefPubMed

49.

Manni R, Terzaghi M, Ratti PL, Repetto A, Zangaglia R, Pacchetti C (2011) Hallucinations and REM sleep behaviour disorder in Parkinson’s disease: dream imagery intrusions and other hypotheses. Conscious Cogn 20:1021–1026CrossRefPubMed

50.

Barnes J, Boubert L, Harris J, Lee A, David AS (2003) Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia 41:565–574CrossRefPubMed

51.

Diederich NJ, Goetz CG, Stebbins GT (2005) Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 20:130–140CrossRefPubMed

52.

Shine JM, Halliday GM, Naismith SL, Lewis SJG (2011) Visual misperceptions and hallucinations in Parkinson’s disease: dysfunction of attentional control networks? Mov Disord 26:2154–2159CrossRefPubMed

53.

Yao N, Shek-Kwan Chang R, Cheung C et al (2014) The default mode network is disrupted in Parkinson’s disease with visual hallucinations. Hum Brain Mapp 35:5658–5666. https://doi.org/10.1002/hbm.22577 CrossRefPubMedPubMedCentral

54.

Adolphs RA, Schul R, Tranel D (1998) Intact recognition of facial emotion in Parkinson’s disease. Neuropsychology 12:253–258CrossRefPubMed

55.

Lin CY, Tien YM, Huang JT, Tsai CH, Hsu LC (2016) Degraded impairment of emotion recognition in Parkinson’s disease extends from negative to positive emotions. Behav Neurol. https://doi.org/10.1155/2016/9287092

56.

Kalampokini S, Lyros E, Luley M et al (2017) Facial emotion recognition in Parkinson’s disease: association with age and olfaction. J Clin Exp Neuropsychol 21:1–11CrossRef

57.

Ricciardi L, Visco-Comandini F, Erro R et al (2017) Facial emotion recognition and expression in Parkinson’s disease: an emotional mirror mechanism? PLoS One 12(1):e0169110. https://doi.org/10.1371/journal.pone.0169110 CrossRefPubMedPubMedCentral

58.

Enrici I, Adenzato M, Ardito RB, Mitkova A, Cavallo M, Zibetti M, Lopiano L, Castelli L (2015) Emotion processing in Parkinson’s disease: a three-level study on recognition, representation, and regulation. PLoS One 10:e0131470. https://doi.org/10.1371/journal.pone.0131470 CrossRefPubMedPubMedCentral

59.

Wabnegger A, Ille R, Schwingenschuh P, Katschnig-Winter P, Kögl-Wallner M, Wenzel K, Schienle A (2015) Facial emotion recognition in Parkinson’s disease: an fMRI investigation. PLoS One 10:e0136110. https://doi.org/10.1371/journal.pone.0136110 CrossRefPubMedPubMedCentral

60.

Gray HM, Tickle-Degnen L (2010) A meta-analysis of performance on emotion recognition tasks in Parkinson’s disease. Neuropsychology 24:176–191CrossRefPubMed

61.

Wagenbreth C, Wattenberg L, Heinze HJ, Zaehle T (2016) Implicit and explicit processing of emotional facial expressions in Parkinson’s disease. Behav Brain Res 303:182–190. https://doi.org/10.1016/j.bbr.2016.01.059 CrossRefPubMed

62.

Santangelo G, Vitale C, Trojano L et al (2012) Neuropsychological correlates of theory of mind in patients with early Parkinson’s disease. Mov Disord 27:98–105. https://doi.org/10.1002/mds.23949 CrossRefPubMed

63.

Poletti M, Enrici I, Adenzato M (2012) Cognitive and affective theory of mind in neurodegenerative diseases: neuropsychological, neuroanatomical and neurochemical levels. Neurosci Biobehav Rev 36:2147–2164. https://doi.org/10.1016/j.neubiorev.2012.07.004 CrossRefPubMed

64.

Costa A, Peppe A, Carlesimo GA, Salamone G, Caltagirone C (2010) Prevalence and characteristics of alexithymia in Parkinson’s disease. Psychosomatics 51:22–28. https://doi.org/10.1176/appi.psy.51.1.22 CrossRefPubMed

65.

Assogna F, Cravello L, Orfei MD, Cellupica N, Caltagirone C, Spalletta G (2016) Alexithymia in Parkinson’s disease: a systematic review of the literature. Parkinsonism Relat Disord 28:1–11. https://doi.org/10.1016/j.parkreldis.2016.03.021 CrossRefPubMed

66.

Godefroy O, Azouvi P, Robert P, Roussel M, LeGall D, Meulemans T (2010) Dysexecutive syndrome: diagnostic criteria and validation study. Ann Neurol 68:855–864CrossRefPubMed

67.

Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatr Clin Neurosci 4:134–139CrossRef

68.

Santangelo G, Barone P, Cuoco S et al (2014) Apathy in untreated, de novo patients with Parkinson’s disease: validation study of the Apathy Evaluation Scale. J Neurol 261:2319–2328. https://doi.org/10.1007/s00415-014-7498-1 CrossRefPubMed

69.

Santangelo G, Raimo S, Siciliano M et al (2017) Assessment of apathy independent of physical disability: validation of the Dimensional Apathy Scale in Italian healthy sample. Neurol Sci 38:303–309. https://doi.org/10.1007/s10072-016-2766-8 CrossRefPubMed

70.

Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for impulsive-compulsive disorders in Parkinson’s disease-rating scale. Mov Disord 27:242–247CrossRefPubMed

71.

Okai D, Askei-Jones S, Mack J, Martin A, Chaudhuri KR, Samuel M, David AS, Brown RG (2016) Parkinson’s Impulse-Control Scale for the severity rating of impulse-control behaviors in Parkinson’s disease: a semistructured clinical assessment tool. Mov Disord 3:494–499CrossRef

72.

Santangelo G, Falco F, D’Iorio A et al (2016) Anxiety in early Parkinson’s disease: validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). J Neurol Sci 367:158–161. https://doi.org/10.1016/j.jns.2016.06.008 CrossRefPubMed

73.

Leentjens AF, Verhey FR, Luijckx GJ, Troost J (2000) The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov Disord 15:1221–1224CrossRefPubMed

74.

Erga AH, Alves G, Larsen JP, Tysnes OB, Pedersen KF (2017) Impulsive and compulsive behaviors in Parkinson’s disease: the Norwegian ParkWest Study. J Parkinsons Dis 7:183–191CrossRefPubMedPubMedCentral

75.

Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1611. https://doi.org/10.1002/mds.26431 CrossRefPubMed

76.

Goerlich-Dobre KS, Probst C, Winter L, Witt K, Deuschl G, Möller B, Eimeren T (2014) Alexithymia—an independent risk factor for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord 29:214–220CrossRefPubMed

77.

Bagby RM, Parker JDA, Taylor GJ (1994) The 20-item Toronto Alexithymia Scale, I: item selection and crossvalidation of the factor structure. J Psychosom Res 38:23–32CrossRefPubMed

Title: Cognitive and behavioral disorders in Parkinson’s disease: an update. II: behavioral disorders
Authors: Luigi Trojano
Costanza Papagno
Publication date: 01-01-2018
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 1/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-017-3155-7

2024 ASCO Annual Meeting

Springer Medicine

Cognitive and behavioral disorders in Parkinson’s disease: an update. II: behavioral disorders

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

TLR4 polymorphisms affect stroke risk and inflammatory response in Chinese ischemic stroke patients

Sudomotor function in diabetic peripheral artery disease: a role for diabetic neuropathy?

Concomitant neurosyphilis and herpes simplex encephalitis in an immunocompetent patient: a case report

Villaret syndrome as clinical presentation of occult metastatic breast cancer

Diagnosis and treatment of severe neurosurgical patients with pyogenic ventriculitis caused by gram-negative bacteria

Central pontine myelinolysis and poorly controlled diabetes: MRI’s hints for pathogenesis